{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03564340",
            "orgStudyIdInfo": {
                "id": "R4018-ONC-1721"
            },
            "secondaryIdInfos": [
                {
                    "id": "2019-003298-24",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers",
            "officialTitle": "A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-administered-alone-or-in-combination-with-cemiplimab-in-adult-patients-with-recurrent-ovarian-cancer-or-other-recurrent-mucin-expressing-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-05-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-05-17",
            "studyFirstSubmitQcDate": "2018-06-08",
            "studyFirstPostDateStruct": {
                "date": "2018-06-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-31",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to:\n\n* Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus\n* The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics\n* The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus\n* To find out how safe and tolerable the sarilumab pretreatment is, in combination with REGN4018 and cemiplimab"
        },
        "conditionsModule": {
            "conditions": [
                "Recurrent Ovarian Cancer",
                "Recurrent Fallopian Tube Cancer",
                "Recurrent Primary Peritoneal Cancer",
                "Recurrent Endometrial Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 690,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "REGN4018 administration",
                    "interventionNames": [
                        "Drug: REGN4018",
                        "Drug: Sarilumab"
                    ]
                },
                {
                    "label": "Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "REGN4018 and cemiplimab administration",
                    "interventionNames": [
                        "Drug: REGN4018",
                        "Drug: cemiplimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "REGN4018",
                    "description": "REGN4018 will be administered in a series of dose escalation and dose expansion cohorts by intravenous (IV) infusion and/or subcutaneous (SC) as described in the protocol.",
                    "armGroupLabels": [
                        "Combination Therapy",
                        "Monotherapy"
                    ],
                    "otherNames": [
                        "Ubamatamab\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "cemiplimab",
                    "description": "Cemiplimab will be administered by IV infusion after REGN4018 monotherapy lead-in phase.",
                    "armGroupLabels": [
                        "Combination Therapy"
                    ],
                    "otherNames": [
                        "REGN2810"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sarilumab",
                    "description": "Sarilumab will be administered by IV, one-time-only, prior to IV/SC REGN4018.",
                    "armGroupLabels": [
                        "Monotherapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Dose-limiting toxicity (DLTs) for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "From Cycle 1, Day 1 up to 35 days"
                },
                {
                    "measure": "Number of participants with DLTs for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "From Cycle 2, Day 1 up to 21 days"
                },
                {
                    "measure": "Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with TEAEs (including imAEs) for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with serious adverse events (SAEs) for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with SAEs for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of deaths for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of deaths for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Concentration of REGN4018 in serum over time for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "ORR defined by RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "ORR based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "ORR based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with TEAEs (including imAEs) for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with TEAEs (including imAEs) for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with SAEs for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with SAEs for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of deaths for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of deaths for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Concentration of REGN4018 in serum over time for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase\n\nThe EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as \"not at all\" and 4 as \"very much.\"",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in abdominal symptoms as measured by the Measure of Ovarian Symptoms and Treatment (MOST)-Abdominal index score for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase excluding the Endometrial Cancer Cohort\n\nThe MOST-24 is a 24-item questionnaire used to measure the impact of chemotherapy on symptoms (21 items) and well-being (3 items). The expected questionnaire completion time is less than 5 minutes.\n\nThe prevalence of each MOST item at assessment time points can be summarized by providing the mean, standard deviation and proportions based on the MOST response format, a numeric rating scale with integers from zero to 10, with five verbal anchors: 'No trouble at all' (0), 'Mild' (1-3), 'Moderate' (4-6), 'Severe' (7-10), and 'Worst I can imagine' (10).",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in abdominal symptoms as measured by the MOST-Abdominal index score for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase Not applicable to Endometrial Cancer Cohort",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in GHS/QoL for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in GHS/QoL for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in physical functioning for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in physical functioning for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in abdominal symptoms for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Time to deterioration in abdominal symptoms for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in QoL as measured by EQ-5D for REGN4018 monotherapy",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "Change from baseline in QoL as measured by EQ-5D for REGN4018 with cemiplimab",
                    "description": "Dose Expansion Phase",
                    "timeFrame": "Baseline up to 62 weeks"
                },
                {
                    "measure": "ORR based on iRECIST for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "ORR based on iRECIST for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Best overall response (BOR) based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "BOR based on iRECIST for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "BOR based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "BOR based on iRECIST for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Duration of response (DOR) based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "DOR based on iRECIST for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "DOR based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "DOR based on iRECIST for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Disease control rate based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Disease control rate based on iRECIST for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Disease control rate based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Disease control rate based on iRECIST for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Complete response (CR) rate based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "CR rate based on iRECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "CR rate based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "CR rate based on iRECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Progression-free survival (PFS) based on RECIST 1.1 for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "PFS based on iRECIST for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "PFS based on RECIST 1.1 for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "PFS based on iRECIST for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Cancer antigen-125 (CA-125) response for REGN4018 monotherapy",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "CA-125 response for REGN4018 with cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Presence or absence of anti-drug antibodies against REGN4018",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                },
                {
                    "measure": "Presence or absence of anti-drug antibodies against cemiplimab",
                    "description": "Dose Escalation and Dose Expansion Phases",
                    "timeFrame": "Up to 62 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Ovarian Cancer Cohorts Only: Patients with histologically or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following:\n\n   1. serum CA-125 level \u22652 x upper limit of normal (ULN) (in screening)\n   2. has received at least 1 line of platinum-containing therapy or must be platinum-intolerant (applicable for dose escalation and non-randomized dose expansion cohorts)\n   3. documented relapse or progression on or after the most recent line of therapy\n   4. no standard therapy options likely to convey clinical benefit\n2. Adequate organ and bone marrow function as defined in the protocol\n3. Life expectancy of at least 3 months\n4. Randomized phase 2 expansion cohort (Ovarian Cancer only): Platinum-resistant ovarian cancer patients who have had 1 to 3 lines of platinum-based therapy as defined in the protocol.\n5. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-Programmed Cell Death Ligand 1 (PD-1) therapy and platinum-based chemotherapy:\n\n   1. MUC16 positivity of tumor cells \u226525% by immunohistochemistry (IHC)\n   2. 1-2 prior lines of systemic therapy\n\nKey Exclusion Criteria:\n\n1. Prior treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy, as described in the protocol\n2. Ovarian Cancer Expansion cohorts only: More than 4 prior lines of cytotoxic chemotherapy\n3. Prior treatment with a MUC16 - targeted therapy\n4. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression, as described in the protocol\n5. History and/or current cardiovascular disease, as defined in the protocol\n6. Severe and/or uncontrolled hypertension at screening. Patients taking anti-hypertensive medication must be on a stable anti-hypertensive regimen\n\nNote: Other protocol Inclusion/Exclusion Criteria apply",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "The General Hospital Corporation d/b/a Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02214",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Mayo Clinic Hospital Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "WITHDRAWN",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "James Care Gynecologic Oncology at Mill Run",
                    "status": "RECRUITING",
                    "city": "Hilliard",
                    "state": "Ohio",
                    "zip": "43026",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.0334,
                        "lon": -83.15825
                    }
                },
                {
                    "facility": "Stephenson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Virginia Commonwealth University Medical Center",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Prince of Wales Hospital",
                    "status": "RECRUITING",
                    "city": "Randwick",
                    "state": "New South Wales",
                    "zip": "NSW 2031",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.91439,
                        "lon": 151.24895
                    }
                },
                {
                    "facility": "Peter MacCallum Cancer Center",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Universitair Ziekenhuis Antwerpen",
                    "status": "RECRUITING",
                    "city": "Edegem",
                    "state": "Antwerp",
                    "zip": "2650",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "Grand H\u00f4pital de Charleroi",
                    "status": "RECRUITING",
                    "city": "Charleroi",
                    "state": "Hainaut",
                    "zip": "6000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.41136,
                        "lon": 4.44448
                    }
                },
                {
                    "facility": "UZLeuven",
                    "status": "RECRUITING",
                    "city": "Leuven",
                    "state": "Vlaams Brabant",
                    "zip": "3000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                    }
                },
                {
                    "facility": "Centre Georges-Francois Leclerc",
                    "status": "RECRUITING",
                    "city": "Dijon cedex",
                    "state": "Bourgogne",
                    "zip": "21079",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.31667,
                        "lon": 5.01667
                    }
                },
                {
                    "facility": "Centre Antoine Lacassagne",
                    "status": "RECRUITING",
                    "city": "Nice",
                    "state": "Cedex 2",
                    "zip": "06189",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.70313,
                        "lon": 7.26608
                    }
                },
                {
                    "facility": "Centre Hospitalier Lyon Sud, Hospices Civils de Lyon",
                    "status": "RECRUITING",
                    "city": "Pierre-Benite",
                    "state": "Lyon",
                    "zip": "69310",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "Centre Regional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest - Institut Bergonie",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "UNICANCER - Centre Francois Baclesse (CFB)",
                    "status": "RECRUITING",
                    "city": "Caen cedex 5",
                    "zip": "14076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.18585,
                        "lon": -0.35912
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif Cedex",
                    "zip": "94800",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Rambam Health Care Campus RHCC - Rambam Medical Center",
                    "status": "RECRUITING",
                    "city": "Haifa",
                    "zip": "3109601",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                },
                {
                    "facility": "The Chaim Sheba Medical Center",
                    "status": "RECRUITING",
                    "city": "Tel Hashomer",
                    "zip": "5265601",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.04195,
                        "lon": 34.85623
                    }
                },
                {
                    "facility": "Fondazione Policlinico Agostino Gemelli IRCCS di Roma",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00168",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Istituto Europeo di Oncologia",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "zip": "20141",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Instituto Nazionale Tumori- Fondazione Pascale",
                    "status": "RECRUITING",
                    "city": "Naples",
                    "zip": "80131",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 40.85216,
                        "lon": 14.26811
                    }
                },
                {
                    "facility": "Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Korea University Guro Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "08307",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Seoul National University College of Medicine",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "3080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "6351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Radboudumc, dept Medical Oncology hp 452",
                    "status": "RECRUITING",
                    "city": "Nijmegen",
                    "state": "Gelderland",
                    "zip": "6500HB",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.8425,
                        "lon": 5.85278
                    }
                },
                {
                    "facility": "Erasmus MC",
                    "status": "RECRUITING",
                    "city": "Rotterdam",
                    "state": "Zuid Holland",
                    "zip": "3000 DR",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "University Medical Center Groningen",
                    "status": "RECRUITING",
                    "city": "Groningen",
                    "zip": "9713 GZ",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 53.21917,
                        "lon": 6.56667
                    }
                },
                {
                    "facility": "Cl\u00ednica Universidad de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "state": "Navarra",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Navarre",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Institut Catala d'Oncologia",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08916",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Institut Catala d'Oncologia",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "8908",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario San Carlos",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Clinico Universitatio Santiago de Compostela",
                    "status": "RECRUITING",
                    "city": "Santiago de Compostela",
                    "zip": "15706",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.88052,
                        "lon": -8.54569
                    }
                },
                {
                    "facility": "University College London Hospitals",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "England",
                    "zip": "NW1 2BU",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Guy's Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "England",
                    "zip": "SE1 9RT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Christie NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "state": "Greater Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "The Royal Marsden NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "state": "London",
                    "zip": "SM25PT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                },
                {
                    "facility": "University of Oxford",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "state": "Oxfordshire",
                    "zip": "OX1 2JD",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                },
                {
                    "facility": "Royal Marsden Hospital - Sutton",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "state": "Surrey",
                    "zip": "SM2 5PT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                },
                {
                    "facility": "Imperial College Healthcare NHS Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "W12 OHS",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000077216",
                    "term": "Carcinoma, Ovarian Epithelial"
                },
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                },
                {
                    "id": "D000005185",
                    "term": "Fallopian Tube Neoplasms"
                },
                {
                    "id": "D000012008",
                    "term": "Recurrence"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005184",
                    "term": "Fallopian Tube Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "asFound": "Recurrent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8328",
                    "name": "Fallopian Tube Neoplasms",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8327",
                    "name": "Fallopian Tube Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2189",
                    "name": "Fallopian Tube Cancer",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}